Wednesday, Jan 3, 2001
South San Francisco, Calif. -- January 3, 2001 --Genentech, Inc. (NYSE: DNA) today announced the appointment of Richard H. Scheller, Ph.D., to senior vice president, Research. Scheller will report directly to Arthur D. Levinson, Ph.D., chairman and chief executive officer, Genentech. He will be a member of Genentech's Executive Committee, chair its Research Review Committee and be responsible for setting strategy for Genentech's research and drug discovery activities. Scheller is expected to assume his post in March.
"Dr. Scheller is a premier scientist in the research community and we are extremely excited that he will be joining Genentech, bringing his breadth of knowledge and experience to our work here," said Levinson. "We look forward to the value he will provide to our already highly effective research organization as we remain at the forefront of research, discovery and the development of medicines."
Scheller, 47, a renowned cell and molecular biologist, currently serves as professor of Molecular and Cellular Physiology and of Biological Sciences at Stanford University Medical Center and is an investigator at the Howard Hughes Medical Institute. Scheller received his first academic appointment to Stanford University in 1982. He was appointed to the esteemed position of professor of Molecular and Cellular Physiology in 1993 and as an investigator in the Howard Hughes Medical Institute in 1994.
Scheller's work has earned him numerous awards including the 1997 National Academy of Sciences Award in Molecular Biology. He is a member of the Academy of Arts and Sciences and the National Academy of Sciences and is on the editorial board of several journals including Cell, Molecular Biology of the Cell and The Journal of Cell Biology. Scheller has served on numerous advisory boards including the National Advisory Mental Health Council of the National Institutes of Health. He has published more than 200 papers in peer-reviewed scientific journals.
"Richard Scheller is held in high esteem by his biomedical colleagues and is widely respected for his creativity, productivity, and affability. He has an inborn talent for picking important scientific problems, asking the right questions, and getting clear-cut answers," said Nobel Laureate Joseph L. Goldstein, professor and chairman of Molecular Genetics, University of Texas Southwestern Medical Center, and chairman, Genentech's Scientific Resource Board. "This is a terrific appointment for Genentech."
Scheller holds a doctorate in chemistry from the California Institute of Technology where he was also a postdoctoral fellow, Division of Biology. He was also a postdoctoral fellow at Columbia University, College of Physicians & Surgeons.
He is filling the position being vacated by Dennis Henner, Ph.D., senior vice president, Research, who plans to retire in March. Henner joined Genentech in 1981 and has held significant roles in the research area of the company.
Scheller joins Genentech as the company plans to break ground this summer on its expansion of the Founder's Research Center, adding 280,000 square feet to provide additional laboratories to support its research efforts. When completed, the Center will be the world's largest biotechnology research facility.
Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved products of biotechnology stem from Genentech science. Genentech markets nine products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #